Company news
Zentalis Pharmaceuticals, Inc. news in 2022
Zentalis Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
November 8, 2022
Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference
November 7, 2022
Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer
October 23, 2022
Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy
October 16, 2022
Zentalis Pharmaceuticals Promotes Co-Founder Kevin Bunker, Ph.D. to Chief Scientific Officer
September 26, 2022
Zentalis Pharmaceuticals Appoints Dr. Carrie Brownstein as Chief Medical Officer
September 18, 2022
Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors
September 11, 2022
Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update
August 8, 2022
Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Conference
August 2, 2022
Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2022
Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary
June 26, 2022
Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President
May 30, 2022
Zentalis Pharmaceuticals Announces Closing of Underwritten Offering of Common Stock
May 17, 2022
Zentalis Pharmaceuticals Appoints Oncology Clinical Development Veteran Dr. Kimberly Blackwell as Chief Executive Officer
May 15, 2022
Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update
May 4, 2022
Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer
April 26, 2022
Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR
April 10, 2022
Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR
April 7, 2022
Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3
March 28, 2022
Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 inhibitor ZN-d5 in Patients with Relapsed or Refractory Light Chain (AL) Amyloidosis
March 21, 2022
Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update
February 23, 2022
Decks in 2022
- Investor Presentation (November 2022)
Investor deck · 56 slides · Nov 9, 2022
- Investor Presentation (August 2022)
Investor deck · 44 slides · Aug 9, 2022
- Investor Day (April 2022)
Investor day · 55 slides · Apr 8, 2022
- Technical Presentation (2022)
Technical · 19 slides · 2022